Industry News
Biotechnology Industry News

As the race to harness CAR-T cells…
As the race to harness CAR-T cells for autoimmune diseases hits a rough patch, a Bay Area biotech is gliding over the potholes with an early sign of efficacy in lupus.
Ahead of its upcoming merger with…
Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs).
Novo has struck a 1.17 billion…
Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform with its obesity and Type 2 diabetes drugs.
ADARx Pharmaceuticals has overshot…
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.
A legal feud unfolding in New York…
A legal feud unfolding in New York is putting a spotlight on the work of a business development veteran who is credited for pioneering one of biopharma’s hottest dealmaking mechanism: the China “NewCo” model.
Travere Therapeutics CEO Eric…
Travere Therapeutics CEO Eric Dube, Ph.D., is stepping down after overseeing the launch of the rare kidney disease drug Filspari.
The Senate Committee on Health,…
The Senate Committee on Health, Education, Labor and Pensions (HELP) today questioned Heidi Overton, M.D., Ph.D., Trump’s pick for FDA commissioner, in a hearing marked by tightrope-walking on issues like vaccines, abortions, flavored vapes and
Fosun Pharma subsidiary Henlius…
Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.
Acadia Pharmaceuticals’ phase 2…
Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3 program.
Merck & Co.’s Brunello trial…
Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion takeover.
Roche has penned a backloaded $2…
Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.
Eli Lilly has committed $100…
Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.
As two Big Pharma players in the…
As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an unblemished safety profile for its potential first-in-class candidate,
The Department of War has awarded…
The Department of War has awarded Flagship Pioneering $47 million to develop medical countermeasure technologies against emerging threats.
Enveda has raised a $311 million…
Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.
Immunovant has stopped development…
Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.
Boehringer Ingelheim has dived…
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.
GSK has been operating a strategy…
GSK has been operating a strategy of “balancing the West and the East” since the Big Pharma’s eyes were opened to the potential of licensing drugs from China two years ago, according to an executive.
As an imposing new competitor…
As an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.
Celldex touted a double phase 3…
Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.

